But revenue from Seagen-acquired Padcev, a cancer treatment, fell short at $409 million. Vyndaqel is also soon to face competition. BridgeBio Pharma (BBIO) gained FDA approval for its treatment for the same heart condition in late November. For the fourth quarter, analysts project 45 cents ...